The trials include: KRAKEN, a randomised phase 2 trial of Muvalaplin, the first oral drug that targets Lipoprotein(a) particles BROOKLYN, which is investigating the safety and efficacy of Obicetrapib ...
While having HDL levels above 60 mgdL is often seen as a sign of good health it’s not a standalone indicator Read ahead to ...
Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and ...
Title: ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in ...
Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...
Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.
On Monday, Eli Lilly And Co (NYSE:LLY) announced Phase 2 results for muvalaplin, an investigational once-daily, orally ...
"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...
American Heart Association Scientific Sessions 2024, Abstract 4171286 - The oral medication muvalaplin may safely lower high ...
Researchers at University of Tsukuba analyzed data from middle-aged workers who had received Specific Health Guidance—a ...
A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...
In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback